Single-cell transcriptome analysis identifies a unique tumor cell type producing multiple hormones in ectopic ACTH and CRH secreting pheochromocytoma

  1. Xuebin Zhang
  2. Penghu Lian
  3. Mingming Su
  4. Zhigang Ji
  5. Jianhua Deng
  6. Guoyang Zheng
  7. Wenda Wang
  8. Xinyu Ren
  9. Taijiao Jiang
  10. Peng Zhang  Is a corresponding author
  11. Hanzhong Li  Is a corresponding author
  1. Chinese Academy of Medical Sciences & Peking Union Medical College, China
  2. Capital Medical University, China

Abstract

Ectopic Cushing's syndrome due to ectopic ACTH&CRH-secreting by pheochromocytoma is extremely rare and can be fatal if not properly diagnosed. It remains unclear whether a unique cell type is responsible for multiple hormones secreting. In this work, we performed single-cell RNA sequencing to 3 different anatomic tumor tissues and 1 peritumoral tissue based on a rare case with ectopic ACTH&CRH-secreting pheochromocytoma. And in addition to that, 3 adrenal tumor specimens from common pheochromocytoma and adrenocortical adenomas were also involved in the comparison of tumor cellular heterogeneity. A total of 16 cell types in the tumor microenvironment were identified by unbiased cell clustering of single-cell transcriptomic profiles from all specimens. Notably, we identified a novel multi-functionally chromaffin-like cell type with high expression of both POMC (the precursor of ACTH) and CRH, called ACTH+&CRH+ pheochromocyte. We hypothesized that the molecular mechanism of the rare case harbor Cushing's syndrome is due to the identified novel tumor cell type, that is, the secretion of ACTH had a direct effect on the adrenal gland to produce cortisol, while the secretion of CRH can indirectly stimulate the secretion of ACTH from the anterior pituitary. Besides, a new potential marker (GAL) co-expressed with ACTH and CRH might be involved in the regulation of ACTH secretion. The immunohistochemistry results confirmed its multi-functionally chromaffin-like properties with positive staining for CRH, POMC, ACTH, GAL, TH and CgA. Our findings also proved to some extent the heterogeneity of endothelial and immune microenvironment in different adrenal tumor subtypes.

Data availability

The raw data of scRNA-seq sequencing reads generated in this study were deposited in The National Genomics Data Center (NGDC, https://bigd.big.ac.cn/) under the accession number: PRJCA003766.

Article and author information

Author details

  1. Xuebin Zhang

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Penghu Lian

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Mingming Su

    Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Zhigang Ji

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Jianhua Deng

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Guoyang Zheng

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Wenda Wang

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Xinyu Ren

    Department of Pathology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Taijiao Jiang

    Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Peng Zhang

    Division of Immunotherapy, Institute of Human Virology, Capital Medical University, Beijing, China
    For correspondence
    zhangpengdyx@163.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6218-1885
  11. Hanzhong Li

    Department of Urology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
    For correspondence
    lihzh@pumch.cn
    Competing interests
    The authors declare that no competing interests exist.

Funding

Chinese Academy of Medical Sciences (2017-I2M-1-001)

  • Hanzhong Li

Chinese Academy of Medical Sciences (2020-I2M-2-003)

  • Taijiao Jiang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Murim Choi, Seoul National University, Republic of Korea

Ethics

Human subjects: Specimen collection was obtained after appropriate research consents (and assents when applicable) and was approved by the Institutional Review Board, Peking Union Medical College Hospital. All information obtained was protected and de-identified. (protocol number: S K431)

Version history

  1. Received: March 16, 2021
  2. Accepted: December 13, 2021
  3. Accepted Manuscript published: December 14, 2021 (version 1)
  4. Accepted Manuscript updated: December 15, 2021 (version 2)
  5. Version of Record published: December 31, 2021 (version 3)

Copyright

© 2021, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,723
    views
  • 257
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xuebin Zhang
  2. Penghu Lian
  3. Mingming Su
  4. Zhigang Ji
  5. Jianhua Deng
  6. Guoyang Zheng
  7. Wenda Wang
  8. Xinyu Ren
  9. Taijiao Jiang
  10. Peng Zhang
  11. Hanzhong Li
(2021)
Single-cell transcriptome analysis identifies a unique tumor cell type producing multiple hormones in ectopic ACTH and CRH secreting pheochromocytoma
eLife 10:e68436.
https://doi.org/10.7554/eLife.68436

Share this article

https://doi.org/10.7554/eLife.68436

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Nicholas J Mullen, Surendra K Shukla ... Pankaj K Singh
    Research Article

    Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway that can be targeted by clinically approved inhibitors. However, despite robust preclinical anticancer efficacy, DHODH inhibitors have shown limited single-agent activity in phase 1 and 2 clinical trials. Therefore, novel combination therapy strategies are necessary to realize the potential of these drugs. To search for therapeutic vulnerabilities induced by DHODH inhibition, we examined gene expression changes in cancer cells treated with the potent and selective DHODH inhibitor brequinar (BQ). This revealed that BQ treatment causes upregulation of antigen presentation pathway genes and cell surface MHC class I expression. Mechanistic studies showed that this effect is (1) strictly dependent on pyrimidine nucleotide depletion, (2) independent of canonical antigen presentation pathway transcriptional regulators, and (3) mediated by RNA polymerase II elongation control by positive transcription elongation factor B (P-TEFb). Furthermore, BQ showed impressive single-agent efficacy in the immunocompetent B16F10 melanoma model, and combination treatment with BQ and dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) significantly prolonged mouse survival compared to either therapy alone. Our results have important implications for the clinical development of DHODH inhibitors and provide a rationale for combination therapy with BQ and immune checkpoint blockade.

    1. Cancer Biology
    2. Cell Biology
    Savvas Nikolaou, Amelie Juin ... Laura M Machesky
    Research Article Updated

    Pancreatic ductal adenocarcinoma carries a dismal prognosis, with high rates of metastasis and few treatment options. Hyperactivation of KRAS in almost all tumours drives RAC1 activation, conferring enhanced migratory and proliferative capacity as well as macropinocytosis. Macropinocytosis is well understood as a nutrient scavenging mechanism, but little is known about its functions in trafficking of signalling receptors. We find that CYRI-B is highly expressed in pancreatic tumours in a mouse model of KRAS and p53-driven pancreatic cancer. Deletion of Cyrib (the gene encoding CYRI-B protein) accelerates tumourigenesis, leading to enhanced ERK and JNK-induced proliferation in precancerous lesions, indicating a potential role as a buffer of RAC1 hyperactivation in early stages. However, as disease progresses, loss of CYRI-B inhibits metastasis. CYRI-B depleted tumour cells show reduced chemotactic responses to lysophosphatidic acid, a major driver of tumour spread, due to impaired macropinocytic uptake of the lysophosphatidic acid receptor 1. Overall, we implicate CYRI-B as a mediator of growth and signalling in pancreatic cancer, providing new insights into pathways controlling metastasis.